Abiraterone and cabazitaxel in prostate cancer

New Protocol: Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • Study

    Phase II, noncomparative, randomized study
    Previosly untreated mCRPC
    Cabazitaxel + AAP (n=42) vs. AAP (n=39)

  • Efficacy

    rPFS: 14.8 vs. 6.4 mos
    mOS: 24.5 vs. 18.3 mos

  • Safety

    Grade≥ 3: Musculskletal pain (13% vs.12%), anemia (11% vs.5 )


    • J Clin Oncol AUG 15; 2023

    Slovin F. Susan et al. Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer

    http://doi.org/10.1200/JCO.22.02639

    Reviewed by Elvin CHALABİYEV, MD on SEP 10, 2023

    Altai Oncology App
    Download Altai Oncology App On App Store
    Download Altai Oncology App On Play Store
    • Chemotherapy Protocols
    • Summarized References
    • Oncology Drug Specs
    • TNM Staging
    • BSA, CrCl Calculator
    Back to top Drag